Want to see TSE:BNXT full AI Analyst Report?
BNXT Stock Chart & Stats
C$0.64
-C$0.02(-3.85%)
At close: 4:00 PM EST
C$0.64
-C$0.02(-3.85%)
Day’s Range― - ―
52-Week RangeC$0.28 - C$1.10
Previous CloseN/A
Volume110.36K
Average Volume (3M)80.86K
Market Cap
C$45.50M
Enterprise ValueC$67.66
Total Cash (Recent Filing)C$12.07K
Total Debt (Recent Filing)C$6.30M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding129,994,550
10 Day Avg. Volume59,081
30 Day Avg. Volume80,860
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Business ModelA platform approach that reformulates existing active pharmaceutical ingredients can shorten development timelines and reduce clinical/regulatory risk versus novel drugs. That supports recurring licensing and partnership revenue streams and scalable margins if products advance to commercial deals.
Patient-centric Delivery NicheSpecializing in patient-friendly delivery formats aligns with structural healthcare trends toward adherence, convenience, and outpatient care. This niche can create durable differentiation and licensing pull from larger pharma seeking new formulations for established drugs.
Improving Cash Burn TrendEvidence the company has reduced cash burn versus earlier years indicates improving operational discipline and cost control. While still negative, a sustained reduction in burn improves runway and increases the chance management can reach value-inflection points with smaller financing rounds.
Bears Say
No Meaningful RevenueZero reported revenue and a collapse from prior small sales means no internal cash generation or commercial validation. Without recurring revenues, the firm remains dependent on financing and has limited ability to scale commercialization or demonstrate product-market fit over the medium term.
Weak Balance SheetA negative equity position combined with meaningful debt and very small total assets constrains flexibility. This structural weakness increases refinancing and dilution risk, limits capacity to fund R&D or partnerships internally, and reduces resilience to execution setbacks.
Sustained Cash BurnPersistent multi-million dollar negative operating and free cash flow implies ongoing reliance on external funding. Continued burn erodes runway, forces repeated financing or asset sales, and raises the probability of dilution before the company achieves commercial revenues or profitable licensing.
BioNxt Solutions News
BNXT FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was C$0.28 and its highest was C$1.10 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is C$45.50M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Aug 31, 2026 which is in 40 days.
How were BioNxt Solutions’s earnings last quarter?
Currently, no data Available
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 129,994,550 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in TSE:BNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications. It also advances psychedelic medicine applications to treat various mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Furthermore, BioNxt is engaged in creating point-of-care diagnostics, comprising rapid tests and biosensor screening tools, aimed at early disease detection, improved treatment efficacy, and enhanced disease management. This diagnostic portfolio features a COVID-19 PCR kit, alongside oral biosensors for peri-implantitis, H1N1 (swine flu), and H5N1 (avian flu). Complementing its development efforts, the company provides analytical testing and consulting services, and is involved in pathogen and oral health diagnostics, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company adopted its current name in November 2022, having previously been known as XPhyto Therapeutics Corp.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Avicanna
―
InnoCan Pharma
―